Fifth Annual Clinical Fellowship Competition from NMD4C and MDC Opens May 1st
Together, NMD4C and MDC are excited to open our 2026 annual funding competition to provide clinical fellowship award(s) in neuromuscular medicine and electromyography (EMG)! This annual funding competition provides one-year salary support ($80, 000) for early-career clinicians to participate in Canadian neuromuscular medicine and EMG fellowship training programs.
This year, the competition dates have been modified to better align with the academic calendar of Canadian residency and fellowship training programs – please note the new spring dates for the clinical fellowship funding competition!
Dates and Timelines
Funding competition opens: May 1, 2025
Application submission deadline: June 12th, 2025
Notification of Funding: July-August 2025
Funds available: July-September 2026
Competition Guidelines
The 2026 competition guidelines are available on the NMD4C website, as well as information on how to submit an application.
Clinical fellowship competition guidelines
If you have any questions about the 2026 competition, please contact network manager Erin Beattie at .
Postdoctoral Research Fellowship Competition to Launch Fall 2025
NMD4C and MDC also hold postdoctoral fellowship awards in neuromuscular disease research as a part of our annual fellowship funding competition. These awards provide salary support for early-career scientists to conduct postdoctoral studies in a Canadian laboratory focused on NMD research. The postdoctoral fellowship competition will continue to take place in the fall. More information on how to apply for this year’s competition will be available in the fall of 2025.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.